Search Results - "Khoja, L."

Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review by Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L.L., Hansen, A.R.

“…Immune checkpoint inhibitor (ICI) monoclonal antibodies (mAbs) targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) or…”
Get full text

Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study by Khoja, L., Atenafu, E.G., Suciu, S., Leyvraz, S., Sato, T., Marshall, E., Keilholz, U., Zimmer, L., Patel, S.P., Piperno-Neumann, S., Piulats, J., Kivelä, T.T., Pfoehler, C., Bhatia, S., Huppert, P., Van Iersel, L.B.J., De Vries, I.J.M., Penel, N., Vogl, T., Cheng, T., Fiorentini, G., Mouriaux, F., Tarhini, A., Patel, P.M., Carvajal, R., Joshua, A.M.

“…Despite the completion of numerous phase II studies, a standard of care treatment has yet to be defined for metastatic uveal melanoma (mUM). To determine…”
Get full text

A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker by Khoja, L, Backen, A, Sloane, R, Menasce, L, Ryder, D, Krebs, M, Board, R, Clack, G, Hughes, A, Blackhall, F, Valle, J W, Dive, C

“…Background: Obtaining tissue for pancreatic carcinoma diagnosis and biomarker assessment to aid drug development is challenging. Circulating tumour cells…”
Get full text

Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance by Khoja, L., Lorigan, P., Dive, C., Keilholz, U., Fusi, A.

“…Circulating tumour cells (CTCs) are cells of solid tumour origin detectable in the peripheral blood. Their occurrence is considered a prerequisite step for…”
Get full text

Mortality within 30 days following systemic anti-cancer therapy, a review of all cases over a 4 year period in a tertiary cancer centre by Khoja, L, McGurk, A, O’Hara, C, Chow, S, Hasan, J

“…Abstract Background The national confidential enquiry into patient outcomes and death (NCEPOD) set important benchmarks in assessing the quality of care…”
Get full text

Eosinophilic Asthma Secondary to Adjuvant Anti-PD-1 Immune Checkpoint Inhibitor Treatment in a Melanoma Patient by Kissoonsingh, P., Sutton, B., Iqbal, Syed U., Pallan, Lalit, Steven, Neil, Khoja, L.

“…Background. Adjuvant immune checkpoint inhibitors are a new standard of care in melanoma. However, the immune related toxicity associated with these agents can…”
Get full text

Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma by Krebs, M, Lopez, J, El-Khoueiry, A, Bang, Y-J, Postel-Vinay, S, Abidah, W, Im, S-A, Khoja, L T, Standifer, N, Jones, G N, Marco-Casanova, P, Frewer, P, Berges, A, Cheung, A, Stephens, C, Felicetti, B, Dean, E, Pierce, A, Hollingsworth, S

Get full text

Choosing a better end point for trials of bone-protective agents by Leibowitz-Amit, R., Khoja, L., Tannock, I.F., Joshua, A.M.

“…There is ongoing debate about the appropriate choice, timing and length of administration of bone protective agents in prostate cancer. In this letter,…”
Get full text

Local Tumor Flare Following Radiosurgery and Ipilimumab (Ipi) for Melanoma Brain Metastases: Increased Immune Response? by Chung, C, Khoja, L, Kurtz, G, Bernstein, M, Joshua, A, Hogg, D, Zadeh, G, Laperriere, N, Menard, C, Millar, B.A, Kongkham, P, Butler, M

Get full text

Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK by Khoja, L, Nolan, K, Mekki, R, Milani, A, Mescallado, N, Ashcroft, L, Hasan, J, Edmondson, R, Winter-Roach, B, Kitchener, H.C, Mould, T, Hutson, R, Hall, G, Clamp, A.R, Perren, T, Ledermann, J, Jayson, G.C

“…Abstract Aims Ovarian cancer is the principal cause of gynaecological cancer death in developed countries, yet overall survival in the UK has been reported as…”
Get full text

Does clinical trial participation improve outcomes in patients with ovarian cancer? by Khoja, L, Horsley, L, Heesters, A, Machin, J D, Mitchell, C, Clamp, AR, Jayson, GC, Hasan, J

“…IntroductionTreatment on a clinical trial is considered to be beneficial to oncology patients. However, supportive evidence for this is scarce. Trial effect…”
Get full text

Homocysteine and cognitive tests as predictors of cognitive decline: A cohort study by Garcia, A, Hemraj, A, Klar, S, Chestney, T, Khoja, L, Day, A

Get full text

The Prognostic Impact of MLH1 Promoter Hypermethylation in Stage I-II Endometrial Cancer Treated with Adjuvant Radiotherapy by Sherwani, Z., Damast, S., Fields, E.C., Shah, S., Beriwal, S., Horne, Z.D., Parks, E., Kidd, E.A., Leung, E.W., Khoja, L. Waleed, Taunk, N.K., Chino, J.P., Huang, C.C., Russo, A.L., Dyer, M.A.A., Albuquerque, K.V., Hathout, L.

“…To examine the impact of MLH1 promoter hypermethylation (MLH1ph) on prognosis and recurrence patterns in stage I-II endometroid endometrial cancer (EEC)…”
Get full text

Validating prognostic models in metastatic uveal melanoma (MUM), an international rare cancers initiative by Khoja, L., Atenafu, E., Joshua, A.M., Ocular Melanoma Group, I.R.C.I.

Get full text

Vulvar Carcinoma: Patterns Of Practice And Clinical Outcomes From A Large Academic Cancer Centre by Khoja, L., Hurst, N., Weiss, J., Liu, Z., Laframboise, S., Clarke, B., Han, K., Milosevic, M., Fyles, A., Dhani, N., Croke, J.M.

Get full text

Mortality within 30days following systemic anti-cancer therapy, a review of all cases over a 4year period in a tertiary cancer centre by Khoja, L., McGurk, A., O’Hara, C., Chow, S., Hasan, J.

“…The national confidential enquiry into patient outcomes and death (NCEPOD) set important benchmarks in assessing the quality of care received by patients dying…”
Get full text

Effect of a Home Program of Hip Abductor Exercises on Knee Joint Loading, Strength, Function, and Pain in People With Knee Osteoarthritis: A Clinical Trial by Sled, Elizabeth A, Khoja, Latif, Deluzio, Kevin J, Olney, Sandra J, Culham, Elsie G

“…Hip abductor muscle weakness may result in impaired frontal-plane pelvic control during gait, leading to greater medial compartment loading in people with knee…”
Get full text

413PDPhase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma by Krebs, M, Lopez, J, El-Khoueiry, A, Bang, Y-J, Postel-Vinay, S, Abidah, W, Im, S-A, Khoja, L T, Standifer, N, Jones, G N, Marco-Casanova, P, Frewer, P, Berges, A, Cheung, A, Stephens, C, Felicetti, B, Dean, E, Pierce, A, Hollingsworth, S

Get full text

53 - Local Tumor Flare Following Radiosurgery and Ipilimumab (Ipi) for Melanoma Brain Metastases: Increased Immune Response? by Chung, C., Khoja, L., Kurtz, G., Bernstein, M., Joshua, A., Hogg, D., Zadeh, G., Laperriere, N., Menard, C., Millar, B.A., Kongkham, P., Butler, M.

Get full text

Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance by Khoja, L, Lorigan, P, Dive, C, Keilholz, U, Fusi, A

“…Circulating tumour cells (CTCs) are cells of solid tumour origin detectable in the peripheral blood. Their occurrence is considered a prerequisite step for…”
Get full text